Comparison of Mean Platelet Volume, Platelet Distribution Width, Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio and Lymphocyte/Monocyte Ratio in Patients with Differentiated Thyroid Cancer According to TSH Levels

Year 2022, , 302 - 310, 27.12.2022

Seher Çetinkaya Altuntaş , Ömercan Topaloğlu

https://doi.org/10.29058/mjwbs.1187429

Cited By: 1

Abstract

Purpose: The standard treatment in differentiated thyroid cancer (DTC) is total thyroidectomy followed by lifelong levothyroxine (LT4) replacement. However, what should be the level of exogenous LT4 and TSH is still a matter of debate.
Material and Method: 162 patients with a prospective diagnosis of non-metastatic DTC and 69 healthy volunteers were included. DTC patients were divided into 3 groups according to their TSH level. If TSH is less than 0.1μIU/mL, between 0.11-0.49 μIU/mL, 0.5-2μIU/mL, the groups were named as suppressed thyrotropin, moderately suppressed thyrotropin and low-normal thyrotropin group, respectively.
Results: No statistical difference was observed between MPV, PDW, NLR, PLR, LMR when the DTC group and the healthy control group were compared. When the patients were divided into 3 groups according to their TSH levels, only PDW levels were found to be higher in the moderately suppressed group compared to the other groups (p <0.001). Besides, a positive correlation was found between TSH levels and LMR (r=0.154, p=0.020), and fT4 levels were negatively correlated with LMR (r=-0.146, p=0.028). In the linear regression analysis, it was found that 1 unit increase in duration of LT4 use increases MPV by 0.070 units (p=0.031), and 1 unit increase in TSH increases LMR 0.517 units (p=0.041). An increase of T3 by 1 unit reduces the NLR by 0.282 units (p=0.032).
Conclusion: In DTC patients, excessive LT4 dose for target TSH level may increase the risk of inflammatory and cardiovascular disease as well as low dose. Each patient should be treated individually and when making LT4 dose adjustment their age, comorbid diseases, and disease stage should be taken into account. Long-term studies are needed to determine what the target TSH optimum value should be.

Keywords

Mean Platelet Volüme;, Differantieted Thyroid Cancer ;, Platelet Distrubition Width

Differansiye Tiroid Kanserli Hastalarda TSH Düzeylerine Göre Ortalama Platelet Volümü, Platelet Dağılım Genişliği, Nötrofil/ Lenfosit Oranı, Platelet/Lenfosit Oranı ve Lenfosit/Monosit Oranının Karşılaştırılması

Abstract

Amaç:Diferansiye tiroid kanseri (DTK) standart tedavi total tiroidektomi ve sonrasında ömür boyu levotiroksin (LT4) replasmanı yapılmasıdır. Fakat ekzojen LT4 ile TSH düzeyinin ne olması gerektiği halen tartışma konusudur.
Gereç ve Yöntemler: Prospekif non metastatik DTK tanısı olan 162 hasta ile 69 sağlıklı gönüllü alındı. DTK hastaları TSH seviyesine göre 3 gruba ayrıldı. TSH: 0,1μIU/mLden küçük ise suprese tirotropin TSH:0,11-0,49 μIU/mLarasında ise ılımlı suprese tirotropin TSH :0,5- 2μIU/mL arasında düşük -normal tirotropin grubu olarak adlandırıldı.
Bulgular:DTK ve sağlıklı kontrol grubu arasında MPV, PDW, NLR,PLR, LMR arasında istatistiksel fark saptanmadı.HastalarTSH düzeyine göre 3 gruba ayrılınca sadece PDW düzeyleri diğer 3 gruba göre ılımlı suprese grupta yüksek saptandı. (p <0,001).Ayrıca TSH düzeyleri ile LMR arasında pozitif yönlü (r=0,154 p=0,020), sT4 düzeyleri LMR ile negatif yönde düşük korelasyon saptanmıştır. (r=-0,146 p=0,028 ) Lineer regresyon analizinde LT4 kullanma süresinin 1 birim artması MPW’ı ortalama 0,070 birim (p=0,031), TSH’ın 1 birim artması LMR’yi ortalama 0,517 birim arttırmaktadır (p=0,041). T3’ün 1 birim artması NLR’ı ortalama 0,282 birim azaltmaktadır (p=0,032).
Sonuç: DTK hastalarında hedef TSH düzeyi için verilen LT4 dozunun fazla olması kadar, az olması da inflamatuar, kardiovasküler hastalık riski artırmaktadır. Her hasta bireysel ele alınıp, yaş, ek hastalıkları, hastalık evresi gibi durumları göz önüne alınarak LT4 doz ayarlaması yapılmalıdır. Hedef TSH optimum değerinin ne olması gerektiği için uzun süreli çalışmalara ihtiyaç vardır.

Keywords

Differansiye Tiroid Kanser ;, Ortalama Platelet Volümü, Ortalama Platelet Dağılımı

References

• 1-Sefik Tagay, Stephan Herpertz, Matthias Langkafel, Yesim Erim, Lutz Freudenberg, Nicole Schööpper, Andreas Bockisch, Wolfgang Senf and Rainer Görges Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment European Journal of Endocrinology (2005) 153 755–76
• 2-Türkiye Endokrinoloji ve Metabolizma Derneği , Tiroid Hastalıkları Tanı ve Tedavi Kılavuzu. 2019 179-181
• 3- Shimodaira M, Niwa T, Nakajima K, Kobayashi M, Hanyu N, Nakayama T. Correlation between mean platelet volume and fasting plasma glucosel evels in prediabetic and normoglycemic individuals. CardiovascDiabetol. 2013 Jan 11;12:14. doi: 10.1186/1475-2840-12-14.  
• 4- Vizioli L, Muscari S, Muscari A: Therelationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J ClinPract 2009, 63:1509–1515. 
• 5- Dastjerdi, M.S.; Emami, T.; Najafian, A.; Amini, M. Mean platelet volume measurement, EDTA or citrate? Hematology, 2006, 11(5), 317-319
• 6-Uysal, E.; Ceylan, S.M.; Sezgin, E.; Bakir, H.; Gurer, A.O.; Aksoy, B.; Bastemir, M. Evaluation of Hemocytometer Parameters as Potential Biomarkers in Benign Multinodular Goiter and Papillary Thyroid Carcinoma. Iran Red Crescent Med J., 2017, 19(12), e58295.
• 7-Machairas, N.; Kostakis, I.D.; Prodromidou, A.; Stamopoulos, P.; Feretis, T.; Garoufalia, Z.; Damaskos, C.; Tsourouflis, G.; Kouraklis, G. Trends in white blood cell and platelet indices in a compari- son of patients with papillary thyroid carcinoma and multinodular goiter do not permit differentiation between the conditions. Endocr. Res., 2017, 42(4), 311-317
• 8- Keskin, H.; Kaya, Y.; Cadirci, K.; Kucur, C.; Ziypak, E.; Simsek, E.; Gozcu, H.; Arikan, S.; Carlioglu, A. Elevated neutrophil- lymphocyte ratio in patients with euthyroid chronic autoimmune thyreotidis. Endocr. Regul., 2016, 50(3), 148-153.
• 9-Bhat, T.; Teli, S.; Rijal, J.; Bhat, H.; Raza, M.; Khoueiry, G.; Meghani, M.; Akhtar, M.; Costantino, T. Neutrophil to lymphocyte ratio and cardiovascular diseases: A review. Expert Rev. Cardio- vasc. Ther., 2013, 11(1), 55-59.
• 10-Celikbilek, M.; Dogan, S.; Ozbakır, O.; Zararsız, G.; Kücük, H.; Gürsoy, S.; Yurci, A.; Güven, K.; Yücesoy, M. Neutrophil- lymphocyte ratio as a predictor of disease severity in ulcerative co- litis. J. Clin. Lab. Anal., 2013, 27(1), 72-76.
• 11-Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.
• 12 -Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–71
• 13-He JR, Shen GP, Ren ZF, Qin H, Cui C, Zhang Y, et al. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(12):1769–76.
• 14-Cheng S, Han F, Wang Y, Xu Y, Qu T, Ju Y, et al. The red distribution width and the platelet distribution width as prognostic predictors in gastric cancer. Bmc Gastroenterol. 2017;17(1):163.
• 15-Lee F, Yang PS, Chien MN, Lee JJ, Leung CH, Cheng SP. An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer. Int J Med Sci. 2018;15(14):1757-1763. Published 2018 Nov 23. doi:10.7150/ijms.28498
• 16-Wen W, Wu P, Li J, Wang H, Sun J, Chen H. Predictive values of the selected inflammatory index in elderly patients with papillary thyroid cancer. J Transl Med. 2018 Sep 21;16(1):261. doi: 10.1186/s12967-018-1636
• 17-Liu, J.; Du, J.; Fan, J.; Liu, K.; Zhang, B.; Wang, S.; Wang, W.; Wang, Z.; Cai, Y.; Li, C.; Yu, T.; Zhu, G.; Chen, J.; Li, C. The Neutrophil-to-Lymphocyte Ratio Correlates with Age in Patients with Papillary Thyroid Carcinoma. ORL J. Otorhinolaryngol. Relat. Spec., 2015, 77(2), 109-116.
• 18- Kim, S.M.; Kim, E.H.; Kim, B.H.; Kim, J.H.; Park, S.B.; Nam, Y.J.; Ahn, K.H.; Oh, M.Y.; Kim, W.J.; Jeon, Y.K.; Kim, S.S.; Kim, Y.K.; Kim, I.J. Association of the Preoperative Neutrophil-to- lymphocyte Count Ratio and Platelet-to-Lymphocyte Count Ratio with Clinicopathological Characteristics in Patients with Papillary Thyroid Cancer. Endocrinol. Metab. (Seoul), 2015, 30(4), 494-501.
• 19- Bayhan, Z.; Zeren, S.; Ozbay, I.; Kahraman, C.; Yaylak, F.; Tiryaki, C.; Ekici, M. Mean Platelet Volume as a Biomarker for Thyroid Carcinoma. Int. Surg. 2015 101, 50-53.
• 20 -Yaylaci, S.; Tosun, O.; Sahin, O.; Genc, A.B.; Aydin, E.; Demiral, G.; Karahalil, F.; Olt, S.; Ergenc, H.; Varim, C. Lack of Variation in Inflammatory Hematological Parameters between Benign Nodular Goiter and Papillary Thyroid Cancer. Asian Pac. J. Cancer Prev. 2016 17(4), 2321-2323
• 21- Dincel, O.; Bayraktar, C. Evaluation of platelet indices as a useful marker in papillary thyroid carcinoma. Bratisl. Lek Listy 2017 118(3), 153-155 22-Kutluturk F, Gul SS, Sahin S, Tasliyurt T. Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma. Endocr Metab Immune Disord Drug Targets. 2019;19(6):859-865.
• 23- Squizzato A, Romualdi E, Bu¨ ller HR, Gerdes VE Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007 92:2415–2420
• 24- Ford HC, Toomath RJ, Carter JM, et al. Mean platelet volume is increased in hyperthyroidism. Am J Hematol.1988;27:190–3.
• 25 -Panzer, S.; Haubenstock, A.; Minar, E. Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indiumlabeled platelet kinetics, and platelet-associated immunoglobulins G and M. J. Clin. Endocrinol. Metab.1990 70(2), 491-496.
• 26 -Hak AE, Pols HAP, Visser TJ, Drexhage HA, Hofman A,Witterman JC Subclinical hypothyroidism is an independent risk factor for artherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Ann Intern Med 2000 132:270–278.
• 27- Erikci AA, Karagoz B, Ozturk A, et al. The effect of subclinical hypothyroidism on platelet parameters. Hematology 2009;14:115–7
• 28 -Lippi, G.; Danese, E.; Montagnana, M.; Nouvenne, A.; Meschi, T.;Borghi, L. Mean platelet volume is significantly associated with serum levels of thyroid-stimulating hormone in a cohort of older euthyroid subjects. Endocr. Res. 2015 40(4), 227-230.
• 29-Kim JH, Park JH, Kim SY, Bae HY. The mean platelet volume ispositively correlated with serum thyrotropin concentrations in apopulation of healthy subjects and subjects with unsuspected subclinical hypothyroidism. Thyroid 2013;23:31–7
• 30-Weiheng Wen,Peili Wu, Jitong Li, He Wang, Jia Sun and Hong ChenPredictive values of the selected inflammatory index in elderly patients with papillary thyroid cancer. Wen et al. J Transl Med 2018 16:261